These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

85 related items for PubMed ID: 8219633

  • 1. [Proliferative vitreoretinopathy. On the significance of protein transfer through the blood-retina barrier].
    Grisanti S, Wiedemann P, Heimann K.
    Ophthalmologe; 1993 Oct; 90(5):468-71. PubMed ID: 8219633
    [Abstract] [Full Text] [Related]

  • 2. The significance of complement in proliferative vitreoretinopathy.
    Grisanti S, Wiedemann P, Weller M, Heimann K, Zilles K.
    Invest Ophthalmol Vis Sci; 1991 Sep; 32(10):2711-7. PubMed ID: 1894471
    [Abstract] [Full Text] [Related]

  • 3. [Proliferative vitreoretinopathy. Activation of the complement system].
    Grisanti S, Esser P, Weller M, Wiedemann P, Heimann K.
    Ophthalmologe; 1992 Feb; 89(1):50-4. PubMed ID: 1533804
    [Abstract] [Full Text] [Related]

  • 4. [Protein composition of the vitreous body in proliferative diabetic retinopathy. An analysis with 2-D-electrophoresis].
    Bresgen M, Baum U, Esser P, Wiedemann P, Heimann K.
    Ophthalmologe; 1994 Dec; 91(6):758-62. PubMed ID: 7849428
    [Abstract] [Full Text] [Related]

  • 5. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study.
    Kon CH, Occleston NL, Aylward GW, Khaw PT.
    Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):705-12. PubMed ID: 10067974
    [Abstract] [Full Text] [Related]

  • 6. Upregulation of RAGE and its ligands in proliferative retinal disease.
    Pachydaki SI, Tari SR, Lee SE, Ma W, Tseng JJ, Sosunov AA, Cataldergirmen G, Scarmeas N, Caspersen C, Chang S, Schiff WM, Schmidt AM, Barile GR.
    Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
    [Abstract] [Full Text] [Related]

  • 7. [Proliferative vitreoretinopathy: new discoveries in pathophysiology and therapy].
    Wiedemann P, Weller M, Heimann K.
    Klin Monbl Augenheilkd; 1990 Nov; 197(5):355-61. PubMed ID: 2290290
    [Abstract] [Full Text] [Related]

  • 8. Intercellular adhesion molecule-1 in proliferative vitreoretinopathy.
    Limb GA, Chignell AH, Cole CJ, Green WT, Webster L, Hollifield RD, Dumonde DC.
    Invest Ophthalmol Vis Sci; 1997 Apr; 38(5):1043-8. PubMed ID: 9113001
    [Abstract] [Full Text] [Related]

  • 9. Soluble TNF receptors in vitreoretinal proliferative disease.
    Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH.
    Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
    [Abstract] [Full Text] [Related]

  • 10. Balance of vascular endothelial growth factor and pigment epithelial growth factor prior to development of proliferative vitreoretinopathy.
    Dieudonné SC, La Heij EC, Diederen RM, Kessels AG, Liem AT, Kijlstra A, Hendrikse F.
    Ophthalmic Res; 2007 Jun; 39(3):148-54. PubMed ID: 17534114
    [Abstract] [Full Text] [Related]

  • 11. [Vitronectin: mediator of cell adhesion in proliferative vitreoretinopathy?].
    Weller M, Wiedemann P, Bresgen M, Heimann K.
    Fortschr Ophthalmol; 1990 Jun; 87(2):221-5. PubMed ID: 1694159
    [Abstract] [Full Text] [Related]

  • 12. [Quantitative determination of 5 vitreal proteins in the normal vitreous body and proliferative retinal diseases].
    Clausen R, Weller M, Hilgers RD, Heimann K, Wiedemann P.
    Fortschr Ophthalmol; 1990 Jun; 87(3):283-6. PubMed ID: 2376377
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.
    Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J.
    Eur Cytokine Netw; 2006 Sep; 17(3):155-65. PubMed ID: 17194635
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunoreactive ET-1 in the vitreous humor and epiretinal membranes of patients with proliferative vitreoretinopathy.
    Roldán-Pallarés M, Rollín R, Mediero A, Martínez-Montero JC, Fernández-Cruz A, Bravo-Llata C, Fernández-Durango R.
    Mol Vis; 2005 Jul 07; 11():461-71. PubMed ID: 16030497
    [Abstract] [Full Text] [Related]

  • 19. Localization and quantitation of blood-retinal barrier breakdown in experimental proliferative vitreoretinopathy.
    Ando N, Sen HA, Berkowitz BA, Wilson CA, de Juan E.
    Arch Ophthalmol; 1994 Jan 07; 112(1):117-22. PubMed ID: 8285878
    [Abstract] [Full Text] [Related]

  • 20. Vitreous leptin levels in retinal disease.
    Maberley D, Cui JZ, Matsubara JA.
    Eye (Lond); 2006 Jul 07; 20(7):801-4. PubMed ID: 16052255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.